- Home
- ENGN vs UROY Comparison
ENGN vs UROY Comparison
Compare ENGN & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ENGN | UROY |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.5M | 601.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ENGN | UROY |
|---|---|---|
| Price | $10.01 | $4.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $22.17 | $4.50 |
| AVG Volume (30 Days) | 250.0K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1,584.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $1.43 |
| 52 Week High | $12.25 | $5.52 |
Technical Indicators
Market Signals| Indicator | ENGN | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 52.05 |
| Support Level | $7.83 | $3.55 |
| Resistance Level | $10.39 | $4.66 |
| Average True Range (ATR) | 0.57 | 0.25 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 60.52 | 79.23 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.